GlassScriptPhysician profile
Andrew R Brown
NPI 1194806489
$6,062.47
in general payments reported to CMS, 2019-2025
34 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $286 · 2021: $793 · 2022: $893 · 2023: $1,121 · 2024: $1,174 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,600.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,335.19 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $476.85 | 2019-2025 | Livdelzi |
| Pfizer INC. | $424.51 | 2019-2025 | |
| Janssen Biotech, INC. | $403.16 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.71 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $241.58 | 2022-2025 | |
| Celgene Corporation | $208.42 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $207.97 | 2020-2025 | Entyvio |
| Lilly USA, LLC | $206.40 | 2022-2025 | Omvoh |
| Qol Medical, LLC | $133.29 | 2023-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $94.87 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $93.52 | 2023-2025 | Dupixent |
| Shockwave Medical, INC | $82.40 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Madrigal Pharmaceuticals | $78.94 | 2024-2025 | Resmetirom, Rezdiffra |
| Phathom Pharmaceuticals, INC. | $77.96 | 2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.30 | 2021-2024 | Dificid |
| Shionogi INC | $66.22 | 2019-2020 | |
| Redhill Biopharma INC. | $63.98 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $61.18 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $54.81 | 2023 | Givlaari |
| Ironwood Pharmaceuticals, INC | $50.52 | 2020-2024 | |
| Boston Scientific Corporation | $46.81 | 2022-2024 | Watchman Access System |
| Ardelyx, INC. | $33.84 | 2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $32.98 | 2020-2021 | |
| Enterra Medical, INC. | $25.32 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.33 | 2025 | Iqirvo |
| Vivus LLC | $18.00 | 2021 | |
| Ethicon US, LLC | $16.35 | 2019 | |
| Braintree Laboratories, INC. | $15.13 | 2019 | |
| Ucb, INC. | $14.82 | 2019 | |
| Alfasigma USA, INC. | $12.67 | 2020 | |
| Allergan, INC. | $12.51 | 2019 | |
| Axonics, INC. | $11.90 | 2021 | |
| Concordia Pharmaceuticals INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.